Digital breast tomosynthesis (DBT) detects significantly more high-risk benign breast diseases than conventional mammography, including lobular carcinoma in situ and atypical hyperplasia, according to a study of 4.47 million screening mammograms from nearly 1.2 million women.
- DBT showed 36% higher detection of overall high-risk benign breast disease compared to conventional mammography
- DBT detected 45% more cases of atypical lobular hyperplasia and 164% more radial sclerosing lesions
- Study analyzed nearly two decades of data (2005-2022) from 97 healthcare facilities across the United States
- High-risk benign breast diseases are associated with increased future breast cancer risk but are not considered cancer precursor lesions
- Researchers recommend further studies on surgical excision outcomes and effectiveness of active surveillance strategies
Digital breast tomosynthesis (DBT) use leads to higher detection of high-risk benign breast diseases (BBDs), according to research published November 17 in Radiology.
Using data spanning nearly two decades, researchers led by Brian Sprague, PhD, from the University of Vermont in Burlington reported that DBT finds more lobular carcinoma in situ (LCIS), atypical lobular hyperplasia, and radial sclerosing lesions compared to conventional mammography.
“Our results provide estimates of high-risk BBD detection rates at screening mammography that are broadly representative of clinical practice in the United States and place these estimates in the context of detection of other malignant and benign diagnoses,” Sprague and colleagues wrote.
Nationally representative estimates are lacking for high-risk BBD detection rates at screening mammography. High-risk BBD includes diagnoses tied to higher future breast cancer risk. However, they show no clear evidence that supports defining these diagnoses as cancer precursor lesions.
Prior research suggests that changes in clinical practice over time may influence the detection of high-risk BBD. The researchers noted that detection rates have not been well characterized.
The Sprague team examined trends in high-risk BBD detection rates at screening mammography in the Breast Cancer Surveillance Consortium (BCSC). This included data collected between 2005 and 2022 for women aged 40 to 79 years at 97 healthcare facilities. The team also evaluated associations between DBT, mammography, and high-risk BBD detection.
Screening mammography detection rates for specific high-risk benign breast disease diagnoses by year among women aged 40–79 years in the Breast Cancer Surveillance Consortium (2005 to 2022). Rates are reported per 1,000 screening mammographic exams. There were statistically significant temporal trends in detection rates for most high-risk benign breast disease diagnoses during the study period.RSNA
Final analysis included about 4.47 million screening mammograms from nearly 1.2 million women.
The researchers reported an overall high-risk BBD detection rate of 1.11 per 1,000 exams. However, they found no evidence of a temporal trend since 2017 (annual percent change [APC] = 5.3%; p = 0.09).
Atypical ductal hyperplasia detection declined from 2009 to 2017 (APC = −7.4%; p < 0.001). However, detection of radial sclerosing lesions (APC = 5.4%) and atypical papillary lesions (APC = 19.0%) increased during the study period (p < 0.001 for both).
Compared to mammography, DBT showed associations with increased detection of the following: high-risk BBD overall (odds ratio [OR] = 1.36), LCIS (OR = 1.37), atypical lobular hyperplasia (OR = 1.45), and radial sclerosing lesions (OR = 2.64). All measures achieved statistical significance.
The results may encourage further research in this area, the study authors wrote. They added that such research could set up accurate estimates of how often high-risk BBD diagnoses are upgraded to cancer at surgical excision, as well as find out the effectiveness of active surveillance and risk-reducing strategies.
A better understanding of high-risk BBD is needed to improve breast-related clinical management, including strategies outlined by the researchers, according to an accompanying editorial by Regina Hooley, MD, from Yale University in New Haven, CT.
“In the current technology era, image-based breast cancer screening will continue to advance, incorporating novel AI deep learning tools, enhanced personalized screening protocols, and precision breast imaging,” Hooley wrote.
Read the full study here.



















